We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MacroGenics Up on Lifting of Partial Hold on Cancer Candidate
Read MoreHide Full Article
MacroGenics, Inc. (MGNX - Free Report) announced that the FDA has lifted the partial clinical hold placed on phase I studies evaluating its antibody monoclonal candidate, MGD009. The company is developing the candidate as monotherapy and in combination therapies for treating various types of cancer.
Shares of MacroGenics closed 2.3% higher on Jan 25 following the news. The company’s shares have declined 41.5% in the past six months compared with the industry’s fall of 5.1%.
The partial clinical hold was placed on the studies in December due to hepatic (liver-related) adverse events reported by the company as observed in the clinical studies. While the restriction put by the regulatory authority denied enrollment of new patients to the studies, it allowed continuation of treatment for the previously enrolled patients with a pre-assigned dose.
The company stated that it worked rapidly to provide a comprehensive response to the FDA by the end of December to avoid significant delay in the study. With the removal of the hold, the company will be able to enroll new patients.
MGD009 is a bispecific DART molecule, which redirects T cells to kill B7-H3 protein expressing cells involved in immune regulation. The candidate helps treat cancer as the targeted protein is over-expressed on a wide variety of cancer cells.
We note that a phase I study is evaluating MGD009 monotherapy in unresectable or metastatic B7-H3-expressing tumors while another phase I study is evaluating the candidate in combination with the company’s anti-pd-1 antibody candidate, MGA012, in relapsed or refractory cancer with similar tumors.
Apart from MGD009, MacroGenics is also evaluating an antibody drug conjugate candidate, MGC018, in advanced solid tumors.
Alder BioPharma’s loss estimates have narrowed from $4.63 to $4.57 for 2018 and from $3.50 to $3.41 for 2019 over the past 30 days. The company delivered positive earnings surprise in three of the four trailing quarters with the average beat being 4.22%.
ACADIA Pharma’s loss estimates have narrowed from $2.00 to $1.99 for 2018 and from $1.77 to $1.72 for 2019 over the past 30 days. The company came up with a positive earnings surprise in three of the four trailing quarters with the average beat being 6.77%.
Five Prime’s loss per share estimates narrowed from $4.32 to $4.30 for 2018 and from $5.26 to $5.06 for 2019 over the past 30 days. The company delivered a positive surprise in two of the four trailing quarters with the average beat being 1.61%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
MacroGenics Up on Lifting of Partial Hold on Cancer Candidate
MacroGenics, Inc. (MGNX - Free Report) announced that the FDA has lifted the partial clinical hold placed on phase I studies evaluating its antibody monoclonal candidate, MGD009. The company is developing the candidate as monotherapy and in combination therapies for treating various types of cancer.
Shares of MacroGenics closed 2.3% higher on Jan 25 following the news. The company’s shares have declined 41.5% in the past six months compared with the industry’s fall of 5.1%.
The partial clinical hold was placed on the studies in December due to hepatic (liver-related) adverse events reported by the company as observed in the clinical studies. While the restriction put by the regulatory authority denied enrollment of new patients to the studies, it allowed continuation of treatment for the previously enrolled patients with a pre-assigned dose.
The company stated that it worked rapidly to provide a comprehensive response to the FDA by the end of December to avoid significant delay in the study. With the removal of the hold, the company will be able to enroll new patients.
MGD009 is a bispecific DART molecule, which redirects T cells to kill B7-H3 protein expressing cells involved in immune regulation. The candidate helps treat cancer as the targeted protein is over-expressed on a wide variety of cancer cells.
We note that a phase I study is evaluating MGD009 monotherapy in unresectable or metastatic B7-H3-expressing tumors while another phase I study is evaluating the candidate in combination with the company’s anti-pd-1 antibody candidate, MGA012, in relapsed or refractory cancer with similar tumors.
Apart from MGD009, MacroGenics is also evaluating an antibody drug conjugate candidate, MGC018, in advanced solid tumors.
MacroGenics, Inc. Price
MacroGenics, Inc. Price | MacroGenics, Inc. Quote
Zacks Rank & Key Picks
MacroGenics currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks fromthe pharma sector include Alder BioPharmaceuticals, Inc. , ACADIA Pharmaceuticals Inc. (ACAD - Free Report) and Five Prime Therapeutics, Inc. . All the three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Alder BioPharma’s loss estimates have narrowed from $4.63 to $4.57 for 2018 and from $3.50 to $3.41 for 2019 over the past 30 days. The company delivered positive earnings surprise in three of the four trailing quarters with the average beat being 4.22%.
ACADIA Pharma’s loss estimates have narrowed from $2.00 to $1.99 for 2018 and from $1.77 to $1.72 for 2019 over the past 30 days. The company came up with a positive earnings surprise in three of the four trailing quarters with the average beat being 6.77%.
Five Prime’s loss per share estimates narrowed from $4.32 to $4.30 for 2018 and from $5.26 to $5.06 for 2019 over the past 30 days. The company delivered a positive surprise in two of the four trailing quarters with the average beat being 1.61%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>